Dr Lal PathLabs reported consolidated revenue of ₹731 crore in Q2 FY26, up 10.7% year-on-year, with EBITDA at ₹224 crore and margin steady at 30.7%. Profit after tax rose 16.4% to ₹152 crore, and earnings-per-share grew 16.2% to ₹18.1. The Board approved a ₹7 interim dividend and a 1:1 bonus issue for shareholders.